x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

CCO Oncology Podcast

Clinical Care Options

Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Clinical Care Options. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.

education courses

All Episodes

00:24:54

Expert Insight on Key Updates and New Clinical Trial...

CCO Oncology Podcast ·

2023/10/13

In this episode, Domenica Lorusso, MD, PhD, and Alexandra Leary, MD, PhD, provide expert insights on key updates and new clinical trial data presented at the ESGO 2023 Congress for cervical, endometrial, and ovarian cancers, including:Long-Term Follow Up From Phase III SIENDO Study of Selinexor vs Pbo Maintenance in Patients With TP53wt Advanced/Recurrent Endometrial Cancer Global, Open-Label, Phase I/IIa of HER2-Targeting ADC (DB-1303) in Recurrent/Metastatic Endometrial CancerPhase III From

en

00:20:58

New Evidence With BTK Inhibitor Therapy in CLL and...

CCO Oncology Podcast ·

2023/10/04

In this episode, Catherine C. Coombs, MD, MS, and Toby Eyre, MBChB, MD, discuss key trials presented at SOHO 2023 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion includes analyses of: Matching-adjusted indirect comparison of 3 randomized phase III trials of ibrutinib for relapsed/refractory CLL Meta-analysis of cardiovascular adverse events with second-generation BTK inhibitors in CLL BRUIN: updated results of pirtobrutinib in

en

00:14:39

New Evidence With BTK Inhibitor Therapy in MCL From...

CCO Oncology Podcast ·

2023/08/17

In this episode, Catherine C. Coombs, MD, and Toby Eyre, MBChB, MD, discuss key trials presented at ICML 2023 evaluating the use of BTK inhibitors in mantle cell lymphoma (MCL). The discussion includes analyses of: Phase II trial of acalabrutinib with rituximab for older patients with untreated MCL BRUIN: updated results of pirtobrutinib in covalent BTK inhibitor–pretreated MCL IMCL-2015 GELTAMO: 5-year update ibrutinib for untreated indolent MCL Presenters: Catherine C. Coombs, MD, MSAssociate

en

00:27:03

New Evidence With BTK Inhibitor Therapy in CLL From...

CCO Oncology Podcast ·

2023/07/28

In this episode, Catherine C. Coombs, MD, MS, and Toby Eyre, MBChB, MD, discuss key trials presented at EHA 2023 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL). The discussion includes analyses of:CLL12: final results of the phase III trial of ibrutinib vs placebo in asymptomatic, treatment-naive CLLSEQUOIA: extended follow-up of zanubrutinib vs BR in treatment-naive CLLCAPTIVATE: 4-year follow-up from the fixed duration cohort of ibrutinib plus venetoclax in CLL/small

en

00:46:02

Expert Insight on Key Updates and New Clinical Trial...

CCO Oncology Podcast ·

2023/06/22

In this episode, Kathleen Moore, MD, MS, and Nicoletta Colombo, MD, PhD, provide expert insights on key updates and new clinical trial data presented at the 2023 ASCO Annual Meeting for cervical, endometrial, and ovarian cancers, including:ENGOT-EN6-NSGO/GOG-3031/RUBY: phase III study of dostarlimab plus chemotherapy followed by dostarlimab maintenance in primary advanced or recurrent endometrial cancer outcomes by BICRCCTG CX.5-SHAPE: phase III trial of radical hysterectomy and pelvic node

en

00:31:38

Expert Insight on New Data From SGO 2023 Informing...

CCO Oncology Podcast ·

2023/05/04

In this episode, David Scott Miller, MD, FACOG, FACS, and Linda Duska, MD, MPH, provide expert insights on practice-changing data and other new findings presented at SGO 2023 in endometrial, cervical, and ovarian cancers, including:NRG GY018: randomized phase III study evaluating standard of care of carboplatin plus paclitaxel with or without pembrolizumab as frontline treatment for patients with endometrial cancerENGOT-EN6/GOG-3031/RUBY: randomized, placebo-controlled phase III study of dostarlimab

en

00:32:21

Practical Insights on Using BCMA-Targeted Therapies...

CCO Oncology Podcast ·

2023/04/26

In this episode, Suzanne Lentzsch, MD, Ph.D., and Joseph Mikhael, MD, MEd, FRCPC, FACP, discuss the role of BCMA-targeted therapies in the management of patients with multiple myeloma, including their experiences and challenges with implementing recent data. This overview will include a discussion of: Considerations with administration, including access challengesSequencing TherapiesFuture developments with BCMA-targeted therapiesPresenters:Suzanne Lentzsch, MD, PhDProfessor of MedicineDivision of

en

00:15:58

Contemporary Approaches to Treating Myelofibrosis: A...

CCO Oncology Podcast ·

2023/04/11

In this episode, John Mascarenhas, MD, and Ruben A. Mesa, MD, FACP, discuss current best practices and emerging approaches for treating patients with myelofibrosis, including:Overall approach to treatmentUse of JAK inhibitors for treating myelofibrosisTreating patients with low plateletsDefining JAK inhibitor failureUnmet needs in treatment and emerging therapeutic options, including momelotinib, luspatercept, ruxolitinib add-on therapy, and other phase III approachesPresenters: John Mascarenhas,

en

00:25:05

BRCA Testing and Adjuvant Therapy in Early Breast...

CCO Oncology Podcast ·

2023/04/05

In this episode, Banu Arun, MD; Allison Butts, PharmD, BCOP; and Marissa Marti-Smith, MSN, APRN, AGNP-C, AOCNP, discuss the role of BRCA testing and adjuvant olaparib in early breast cancer, including their experiences and challenges with implementing recent data. This overview will include discussion of: Data supporting the use of adjuvant PARP inhibition in early breast cancer and impact on BRCA testing and clinical practice The multidisciplinary role in ensuring that BRCA testing is completed

en

00:15:48

Experts Discuss Claudin 18.2: A New Target for...

CCO Oncology Podcast ·

2023/03/28

In this podcast episode, Samuel Klempner, MD, and Gregory Botta, MD, PhD, provide expert commentary on the rationale and development of novel agents under investigation for targeting claudin 18.2 in gastric and gastroesophageal cancers, with topics including:Expression patterns and function of the claudin family of proteins in normal gastric tissuesBiologic rationale for utility of claudin 18.2 as an actionable therapeutic target in oncologyPrognostic implications of claudin 18.2 overexpression in

en

00:21:28

Treatment Considerations for Patients With Essential...

CCO Oncology Podcast ·

2023/02/23

In this podcast episode, Prithviraj Bose, MD, and Andrew Kuykendall, MD, discuss their contemporary approaches to the treatment of patients with essential thrombocythemia. The topics covered include:When to use cytoreduction therapies and which therapies to use in low-risk patientsType 1 and type 2 CALR mutations and addressing patient concerns with data from sequencing reportsExperts’ thoughts on therapy options in higher-risk patientsPresenters:Prithviraj Bose, MDAssociate ProfessorDivision of

en

00:26:12

FAQs on the Use of Asparaginase Therapy in Young and...

CCO Oncology Podcast ·

2023/02/20

In this episode, Daniel J. DeAngelo, MD, PhD; Kjeld Schmiegelow, MD, DMSci; and Emily Curran, MD, answer key questions asked by the audience during a live satellite symposium at the 2022 American Society of Hematology Annual Meeting on optimizing pediatric or pediatric-inspired regimens containing asparaginase for the treatment of young and older adults with acute lymphoblastic leukemia.Topics discussed include:Practical considerations for management of allergy-like reactions and hypersensitivity to

en

00:21:59

Experts Answer Questions on Personalized Management...

CCO Oncology Podcast ·

2023/02/17

In this podcast, Rami Komrokji, MD; María Díez Campelo, MD, PhD; and Amer Zeidan, MBBS, MHS answer questions from an audience of healthcare professionals on topics related to personalized management of myelodysplastic syndromes including: Practical use of the Molecular International Prognostic Scoring System Mutational targets and other treatments in ongoing clinical trialsProphylaxis with venetoclax therapyBest practices for bone marrow transplant, including induction and salvage

en

00:16:27

Experts Answer Questions on the Management of...

CCO Oncology Podcast ·

2023/02/17

In this podcast episode, Steven M. Horwitz, MD; Pamela B. Allen, MD, MSc; and Kerry Savage, MD, MSc, answer questions from an audience of healthcare professionals on topics related to the management of T-cell lymphomas, including:Use of brentuximab vedotin in ≤1% CD-30‒expressing lymphomasStrategies with JAK inhibition and epigenetic agentsAllogeneic transplantation in cutaneous T-cell lymphomaPresenters: Steven M. Horwitz MDMember, Memorial Sloan Kettering Cancer Center Attending Physician,

en

00:36:17

Individualizing Care for Patients With...

CCO Oncology Podcast ·

2023/01/18

In this podcast episode from a live CCO Cancer Conversations webinar, Mark Pegram, MD, and Sara Tolaney, MD, MPH, provide expert perspectives on optimal treatment strategies for patients with triple-negative breast cancer (TNBC), with topics including:Current data and strategies for using PD-1/PD-L1 inhibitors in early-stage TNBC Clinical implications of PD-L1 status on therapeutic planning for patients with metastatic TNBC Current data and treatment strategies and the future of antibody–drug

en

00:15:51

Contemporary Approaches to Treating Polycythemia...

CCO Oncology Podcast ·

2023/01/11

In this podcast episode, Raajit Rampal, MD, PhD, and Brady L. Stein, MD, MHS, discuss their contemporary approaches to the treatment of patients with polycythemia vera. The topics covered include:Patient presentation and goals of frontline therapyConsiderations for second-line therapy in the setting of treatment intoleranceExperts’ thoughts on the potential of early intervention to alter disease progressionPresenters:Raajit Rampal, MD, PhDAssociate MemberAssociate Attending PhysicianLeukemia

en

00:31:24

HCC Surveillance: Challenges and Opportunities

CCO Oncology Podcast ·

2023/01/03

In this episode, David Kaplan, MD, MSc, and Tamar Taddei, MD, discuss which patients should be screened for hepatocellular carcinoma, current surveillance recommendations, barriers to implementation, emerging biomarkers in development, and unmet needs in hepatocellular carcinoma surveillance. Presenters:David E. Kaplan, MD, MScAssociate ProfessorPerelman School of MedicineChief, Hepatology Section Division of Gastroenterology and Hepatology University of PennsylvaniaDirector of HepatologyCorporal

en

00:09:23

A Patient’s Perspective on Effective Communication...

CCO Oncology Podcast ·

2022/12/13

In this episode, Zoe Lanham, a woman with high-risk hormone receptor–positive/HER2-negative early breast cancer, discusses the importance of effective communication between patients and their healthcare team, drawing on her personal experience. Presenter:Zoe LanhamPatientLink to full program:https://bit.ly/3Fukjzk

en

00:46:35

The Transgender Cancer Experience: A Conversation...

CCO Oncology Podcast ·

2022/11/29

In this episode, activist and breast cancer survivor Yee Won Chong shares his experience as a transmasculine person navigating the healthcare system with Norma Steiner, MD, a gynecologic oncologist, who in turn offers her perspective on caring for patients across the gender spectrum. Topics include:4 aspects of transgender care: emotional, social, medical, legalGetting language right and how to gracefully recover from fumblesSensitively approaching ongoing cancer care in transmasculine and

en

00:27:21

Expert Thoughts on Studies of Interest Presented at...

CCO Oncology Podcast ·

2022/11/29

In this episode, Prof Isabelle Ray Coquard, MD, PhD, and Ignace Vergote, MD, PhD, share their thoughts on key studies of interested presented at the 2022 ESGO annual meeting in Berlin, Germany, including:• Phase III CALLA trial of durvalumab combined with and following chemoradiotherapy in locally advanced cervical cancer • Geneva HRD test: validation of samples from PAOLA-1 dataset using Geneva laboratory–developed test • Validation of NOGGO-GIS HRD assay using samples from the PAOLA-1 trial •

en

217 results

Similar Podcasts

Science Talk

Albert Einstein College of Medicine

五分钟心理学

柠檬心理

Daily Facts

Amalia Dupray and Montgomery Jones.

Les dents et dodo

BFMTV

Veterinary Clinical Podcasts

The Royal Veterinary College